Ticagrelor
Class
Antiplatelets
Subclass
P2Y12 inhibitors
Substance name
Ticagrelor
Brand names
Brilinta®
Common formulations
Tablet
Dosage and administration
Adults patients
Treatment
Cardiovascular mortality in patients with myocardial infarction
Prevention
Cardiovascular mortality in patients with acute coronary syndromes
Stroke in patients with AIS • NIH Stroke Scale score ≤ 5
TIA
Indications for use
Labeled indications
Adults
Safety risks
Boxed warnings
Exacerbation of bleeding
Contraindications
Hypersensitivity to ticagrelor or any of its components
Warnings and precautions
Cardiac arrhythmias, bradycardia
Dyspnea
Exacerbation of central sleep apnea, Cheyne-Stokes respirations
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Consider alternative agents that may be safer.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource